ALGM · Allegro MicroSystems, Inc.

Current Thesis

Allegro MicroSystems' data-center growth supports a tentative recovery thesis, settled by a weekly close above $40 before a weekly close below $34.10. The operating evidence is management's 2026-07-30 report that data center reached 17% of quarterly sales; the recovery interpretation remains an inference. Company results.

The September refresh weakens the price case: the adjusted reference close was $34.10 on 2026-09-18, versus $36.61 on 2026-09-04. The narrative is dead as the June valuation-expansion leg — the latest close remains below the former $50 reclaim shelf and the $40 level whose August break was documented in the 2026-09-06 coverage. The narrower recovery case carries low conviction; it does not establish that a base has formed.

As checked on 2026-09-20, the company's press-release index still leads with the 2026-07-30 results. No subsequent company release was verified, leaving those results as the latest confirmed operating evidence. Company press releases.

Bullish and bearish views on Allegro MicroSystems, Inc.

The model's bull view on Allegro MicroSystems, Inc. (ALGM), in brief: Operating growth remains measurable. Allegro reported fiscal first-quarter sales of $259.24 million and adjusted diluted earnings per share of $0.23 on 2026-07-30. These provide operating support for the recovery hypothesis, although the 2026-09-18 close does not confirm a price… The bear view: Price deterioration continued after coverage. Both cases follow in full.

Bull Case

• Operating growth remains measurable. Allegro reported fiscal first-quarter sales of $259.24 million and adjusted diluted earnings per share of $0.23 on 2026-07-30. These provide operating support for the recovery hypothesis, although the 2026-09-18 close does not confirm a price recovery. Filed results.
• Data-center demand reached reported revenue. On the 2026-07-30 earnings call, management reported 32% sequential data-center growth and forecast that fiscal 2027 data-center revenue would more than double year over year. That forecast belongs to management; a withdrawal would undermine the operating rationale.

Bear Case

• Price deterioration continued after coverage. The supplied adjusted series records a three-month decline of 44.6% and a close 51.0% below the 52-week high on 2026-09-18. Those measurements contradict an established recovery.
• Analyst revisions challenged the premium. TD Cowen reduced its target to $48 from $66 on 2026-07-31, while Morgan Stanley raised its target to $52 from $51 that day. The disagreement is observable; the revisions alone do not establish whether earnings expectations or valuation assumptions caused the subsequent decline. Benzinga analyst history.
• Guidance remains an unresolved test. Allegro's 2026-07-30 outlook calls for fiscal second-quarter revenue of $265–275 million. A reported result below $265 million would break the operating support for recovery. Filed outlook.

Setup & Price Structure

The 14-day relative strength index (RSI) improved to 40.9 on 2026-09-18 from 26.0 on 2026-09-04, while the dated closes moved lower. This is a measured momentum improvement, but the available observations are too sparse to establish a durable reversal. No moving-average value or trading-volume series is supplied.

The $40 recovery threshold refers to the market level reported broken on 2026-08-18 in the prior coverage. The $34.10 invalidation threshold uses the 2026-09-18 reference close; it is an explicit research boundary, not demonstrated support.

The prior filing review identified planned insider sales dated 2026-08-12 and 2026-08-18. Those disclosures establish historical selling, without proving current insider activity or crowded ownership. Current short interest, fund flows and a representative retail-sentiment sample are missing.

Catalyst Calendar (next 30 days)

• 2026-09-25 — Fiscal second-quarter end. The 2026-07-30 filed outlook explicitly dates the period end, replacing the earlier estimate. This is an accounting cutoff, with no results release established for that date. No confirmed company announcement was identified for the window through 2026-10-20. Filed outlook.
• ~2026-10-29, estimated — Fiscal second-quarter results. Outside the immediate window, this is the next operating test of the revenue outlook and management's data-center forecast. MarketBeat estimates the date from past reporting schedules; company confirmation remains missing. Earnings calendar.

What Would Change Our Mind

Failure to preserve the September reference close would end this recovery hypothesis: a weekly close below $34.10 is the price invalidation. A weekly close above the previously broken $40 level before that breach would satisfy the defined price-recovery case. Neither outcome would restore the already-broken June thesis retroactively.

The operating interpretation would fail independently if fiscal second-quarter revenue fell below the $265 million floor issued on 2026-07-30, or management withdrew its more-than-double fiscal 2027 data-center growth forecast. These are observable tests; an unconfirmed earnings date passing would not itself establish operating failure.

Correlation Notes

This remains a single-name recovery hypothesis; no current theme-cluster evidence establishes broader participation. The prior coverage recorded ALGM falling 9.6% on 2026-08-18 while a broad semiconductor gauge fell 5%. That session documents coincident weakness, but the sample is too small to support a stable correlation or sensitivity estimate.